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ABSTRACT
Introduction: HIV patients are now having
longer life expectancies with the use of
antiretroviral therapy (ART). However, the issue
of mental illness has surfaced with depression
being the most common in these patients,
which has markedly reduced patient adherence
to ART. In Cameroon, the management of HIV/
AIDS does not incorporate psychiatric manifes-
tations and depression is therefore underdiag-
nosed. The aim of our study was to determine
the prevalence and determinants of depressive
symptoms and their association with adherence
to ART among HIV/AIDS patients on HAART in
the Southwest Regional Hospitals of Cameroon.
Methods: This was a cross-sectional hospi-
tal-based study carried out in the BRH and LRH
over a 3-month period. Three hundred HIV
patients aged 21 and above were recruited.
Depression and adherence to treatment were
assessed using the nine-item Patient Health
Questionnaire (PHQ-9) and eight-item Morisky
Medication Adherence Scale questionnaires,
respectively. Data were analysed using Epi-info
version 3.4.5.
Results: The prevalence of depression was
26.7% (95% CI 20.6–33.7%); 75.0% of those
with depression were non-adherent to HAART
compared to 37.3% of those without depression
(p value\0.001). The statistically significant risk
factors associated with depression were unem-
ployment (OR 2.38; 95% CI 1.26–4.50), age
B40 years (OR 2.13; 95% CI 1.20–3.70) and CD4
counts B200 cells/ll (OR 3.70; 95% CI
1.45–9.09).
Conclusion: The prevalence of depression was
high and depression was significantly associated
with non-adherence to HAART. Interventions
to enhance early identification and treatment of
depression in patients with HIV/AIDS are nee-
ded. Depression screening should be included as
part of the routine consultation of HIV/AIDS
patients to ensure early detection and
treatment.
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HIV/AIDS is a major cause of disability and
death, particularly in low- and middle-income
nations [1]. The first cases were reported in 1981
and from the beginning of the pandemic more
than 3 decades ago to the end of 2015, about
35 million (29.6–40.8 million) people have died
of HIV/AIDS-related illnesses [2] with Sub-Sa-
haran Africa being the most affected, account-
ing for 74% of AIDS-related deaths worldwide in
2013 [3]. Nearly 30 years after its discovery, HIV
infection remains the number one cause of
disease-related mortality in Sub-Saharan Africa
[4]. Globally, 36.7 million (34.0–39.8 million)
people were living with HIV(PLWH) at the end
of 2015 with approximately 70% residing in
Sub-Saharan Africa [5], an area with only
approximately 12% of the world’s population.
Sub-Saharan Africa also accounted for 410,000
cases of new HIV infection in 2015 [6]. Recent
estimates set the prevalence of HIV/AIDS in
Cameroon to be 4.46% in adults aged 15–-
49 years as of 2015 [7].
Mental health and HIV/AIDS are closely
interlinked. Mental health problems are associ-
ated with an increased risk of HIV/AIDS infec-
tion and interfere with the treatment;
conversely some mental disorders occur as a
direct result of HIV infection [1]. Depression
contributes significantly to disease morbidity
and affects people in all communities across the
globe. Depression nowadays is estimated to
affect 350 million people [8]. It is well known
that major depressive disorder (MDD) is the
most common prevalent neuropsychiatric
symptom in HIV-1 patients [9]. Depression and
HIV/AIDS are forecasted to be the world’s two
leading causes of disability by 2030 [10].
Research has shown those individuals who are
infected with HIV are more likely to develop
depression than the general population.
Depression affects an individual’s ability to
comply with HIV/AIDS treatment, as well as
quality of life and lifespan [11]. Depression may
seem like an inevitable reaction to being
diagnosed with HIV/AIDS; however it is a sep-
arate illness that can and should be treated,
even when a person is on antiretrovirals [12].
Depression is a distressing and impairing con-
dition that has detrimental effects on many of
the self-care behaviours necessary for optimal
management of HIV [13]. For instance, patients
with depression tend to initiate ART at higher
HIV-1 RNA levels and at lower CD4 cell counts
compared to their non-depressed counterparts
[14]. In addition, depression has been closely
connected to poor adherence to ART once ini-
tiated [15].
Data on the prevalence of depression in
HIV-infected patients are conflicting. A study
carried out in South Africa gave the prevalence
of depression in HIV patients as 42.4% [16].
Similarly a systematic review and meta-analysis
carried out in 2014 from studies of low-, middle-
and high-income countries on 42,366 HIV
patients showed a prevalence of depression
ranging from 12.8% to 78% (there was no sig-
nificant difference in the rate of depressive
symptoms in HIV patients across low-, middle-
and high-income countries) and found that the
likelihood of achieving good adherence was
42% lower in patient with depressive symptoms
compared to those who were not [11]. However,
a lower prevalence of major depressive disorder
(8.1%) was reported in a study carried out in
HIV/AIDS patients in a semi-urban district in
Uganda [17]. This difference in prevalences can
be due to a number of factors such as differences
in study methodology (use of patient self-re-
ports versus structured diagnostic instruments
or differences in study populations, semi-urban
versus urban). A study carried out in Yaounde´,
Cameroon, on newly diagnosed HIV-infected
patients revealed that 63% of the study popu-
lation had depressive symptoms [18]. Also,
research carried out among HIV-infected
patients on ART in a semi-urban centre in
Cameroon reported that one in five participants
met the lifetime criteria for major depression
disorders [19].
Thus, this research aimed at providing data
on the prevalence and determinants of depres-
sion and its association with adherence to ART
among HIV/AIDS patients on HAART in the
Southwest Regional Hospitals of Cameroon in
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view of ameliorating mental health interven-
tions for patients living with HIV/AIDS in the
Cameroon, as well as Africa as a whole, by
establishing standard guidelines.
METHODS
Study Design and Setting
This was a cross-sectional, hospital-based study
conducted at the Buea Regional Hospital (BRH)
and Limbe Regional Hospital (LRH) in the
Southwest Region of Cameroon, Fako division.
The study was carried out for a 3-month period
(16 October 2014 to 12 January 2015).
Patients
The study included HIV/AIDS patients on
HAART at the Buea Regional and Limbe Regio-
nal Hospitals’ day care centre during the study
period. This included both male and female
patients aged 21 years and above. We recruited
316 participants and eliminated 16 (12 with no
CD4 counts, 4 withdrawals of consent). Partic-
ipants were selected using a consecutive con-
venience sampling method. Patients present at
the centres on days of study who were eligible
and who consented were included in the study.
Inclusion Criteria
• HIV patients on HAART for at least the past
6 months with CD4 counts measured within
the last 6 months.
• HIV patients aged 21 years and above.
• HIV patients who offered consent and signed
the study consent form.
Exclusion Criteria
• Less than 6 months post-partum.
• Patients who had lost a loved one within the
last 3 months because they are likely to
present with post-traumatic depression.
• Acutely ill patients.
Study Procedures
Data Collection
We used consecutive convenience sampling
until the desired sample size was reached. Dur-
ing routine clinic days, all potential study par-
ticipants aged 21 years or older were
approached and invited to participate in the
study. The aim of the study, including the risks
and benefits, was explained well in both the
Pidgin and English languages to all the patients
present. Patients indicating interest signed the
consent form provided by the investigator while
waiting for drug distribution and were then
interviewed in private. A pre-designed and val-
idated questionnaire was administered by the
principal investigator to each participant. The
questionnaire contained:
• Demographic data: age, sex, educational level,
occupation, marital status and residence.
– The nine-item Patient Health Question-
naire (PHQ-9), a validated depression
screening tool based on the Diagnostic
and Statistical Manual of Mental Disor-
ders, 4th Edition (DSM-IV) criteria [31].
A PHQ-9 score C10 has a sensitivity of
88% and a specificity of 88% for major
depression, which has led to its promi-
nence in the primary care setting [20].
The advantages of the PHQ-9 question-
naire include that it is shorter than other
depression rating scales, e.g., the Geri-
atric Depression Scale, which is a 15-item
questionnaire, can be administered in
person by a clinician, by telephone or
self-administered, facilitates diagnosis of
major depression, provides assessment of
symptom severity, is well validated and
documented in a variety of populations
and can be used in adolescents as young
as 12 years of age [21]. However, the
PHQ-9 is not without drawbacks as it is
very limited in identifying depressed
individuals with dysthymia (hence false
negatives) [22].
• The Eight-Item Morisky Medication Adher-
ence Scale, a well-known scale used to assess
adherence to treatment in chronic diseases,
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was used to assess medication adherence.
The scale assesses adherence with scores
ranging from 0 to 8.
• Questions assessing risk factors for
depression.
• At the end of each day, the questionnaires
were checked, validated and then stored for
subsequent use for data entry.
Statistical Analysis
Data from the questionnaire were entered into
Microsoft Excel 2010 and imported into Epi info
for statistical analysis. Depression was based on
the PHQ-9 scores, which range from 0 to 27.
Depression was defined by a PHQ-9 score C5
[23] and severity was characterised as none
(0–4), mild (5–9), moderate (10–14), moderately
severe (15–19) and severe (C20).
Adherence was defined as adherent (high)
with a Morisky Medication Adherence Scale
score of 0 and non-adherent (medium, low)
with a score of C1.
The study population was appropriately
described according to age, gender, level of
education, employment status and marital sta-
tus using appropriate charts and frequency
tables. Descriptive statistics were depicted using
absolute numbers, percentages, ranges and
means as appropriate.
The prevalence of depression was com-
puted by univariate analysis and expressed as
a percentage. Age, gender, employment status,
marital status, level of education, family his-
tory of depression, alcohol consumption,
smoking, living companion, funding source,
CD4 count, duration from diagnosis of HIV
infection, duration of treatment and HAART
regimen were assessed for any significant
association to depressive symptoms using the
chi-square test and Fisher’s exact test when
appropriate. A p value of\0.05 was considered
statistically significant. Significant factors
obtained from bivariate analysis were entered
into a multivariate logistic regression model
for control of potential confounders. Chi-s-
quare test was used to analyse significant
associations between depression and non-ad-
herence to HAART.
Compliance with Ethics Guidelines
All procedures performed in studies involving
human participants were in accordance with
the ethical standards of the institutional review
board of the Faculty of Health Sciences,
University of Buea-Cameroon, and with the
Declaration of Helsinki of 1964, as revised in
2013, or comparable ethical standards.
Informed consent was obtained from all




Three hundred sixteen participants were recruited
and 300 were retained. Of the 16 excluded, 12 did
not have CD4 counts and 4 withdrew their con-
sent. The ages of the study participants ranged
from 22 to 74 years with a mean age of
40.9 ± 9.7 years. There were more participants
between the ages of 31–40 years (38.3% of par-
ticipants) compared to any other age group. Of
the 300 study participants 80 (26.7%) were males,
most were employed, i.e. 234 (78.0%), 140
(46.7%) reported being married and most had
primary as the maximum level of education,
representing 52.7% (Table 1).
Prevalence and Severity of Depressive
Symptoms
Of our 300 participants, 80 had depressive
symptoms giving a prevalence of 26.7% (95% CI
20.6–33.7%). Of the 80 participants with
depression, 70 (23.3%) had mild depression, 8
(2.7%) had moderate depression, 2 (0.7%) had
moderately severe depression and none had
severe depression (Table 2).
Assessment of Factors Associated
with Depression
Demographic Factors
Of our 300 participants, the proportion of
patients B40 years with depression was
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significantly higher than those [40 years
(p value = 0.02). Unmarried participants had a
higher prevalence of depression (31.9%) com-
pared to married participants (20.7%). This dif-
ference was statistically significant
(p value = 0.03). Employment status was also
significantly associated with having depression
Table 1 Sociodemographic and clinical characteristics of
the study population (N = 300)




























































TLE tenofovir, lamivudine, efavirenz; ZLN zidovudine,
lamivudine, nevirapine; TLN tenofovir, lamivudine, nevi-
rapine; TLLI tenofovir, lamivudine, lopinavir, indinavir
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(p value = 0.02). Other factors such as gender
and educational status were not found to be
significantly associated with depressive symp-
toms (Table 3).
Social Factors
Depression among participants who did not
have a living companion (41.1%) was higher
than that among those living with someone
(23.4%). The difference was statistically signifi-
cant (p value = 0.01) (Table 3).
Clinical factors
Of the 300 participants, the prevalence of
depression in participants with CD4 count
B200 cells/ll was significantly higher than
that in participants with a CD4 count
[200 cells/ll (52.2% vs. 24.9%, p value =
0.01) (Table 4).
Multivariate Analysis for Factors Associated
with Depression
In the multivariate analysis, we adjusted for
factors associated with depression that had a
p value\0.05 in the bivariate analysis (age,
marital status, employment status, living com-
panion and CD4 count). After multivariate
logistic regressions, age B40, unemployment
and CD4 count B200 cells/ll were found to be
independently associated with depressive
symptoms (Table 5).
Non-adherence
Of our 300 participants 142 (47.3%) were
non-adherent as opposed to 158 (52.7%) who
were adherent to treatment.
Adherence Pattern Among Patients
with and without Depressive Symptoms
Among the 80 participants with depressive
symptoms, 75.0% were non-adherent to treat-
ment as compared to 37.3% of those without
depression. This difference was statistically sig-
nificant (p value\0.001). For adherence pattern
logistic regression, we adjusted for depression as
a potential confounder. Running a logistic
regression, those with depression were 5.04
times more likely to be non-adherent than
those without depression (95% CI 2.84–8.97,
p value \0.001); hence, depressive symptoms
were associated with non-adherence to HAART.
DISCUSSION
We carried out a cross-sectional study on HIV/
AIDS patients receiving antiretroviral therapy at
the SW Regional Hospitals of an urban area in
Cameroon. Our main objective was to deter-
mine the prevalence of depressive symptoms
amongst HIV/AIDS patients on HAART, its
determinants and its influence on adherence
amongst patients accessing care in the treat-
ment centres of the BRH and LRH. We recruited
300 participants of whom 73.3% were females.
The mean duration on HAART was
47.6 ± 36.8 months with a minimum of
6 months.
The prevalence of depressive symptoms was
26.7% which was in accordance with that
observed in the general population (the lower
PHQ9 threshold was used, i.e. PHQ 9 score C5).
Prior studies have shown prevalence of depres-
sion among HIV-infected patients of 7% to 63%
[18, 19]. Such variations may be explained by
the different instruments used to diagnose
depression and by other methodological differ-
ences, such as the cut-off points used and dif-
ferences in the study population. This high
prevalence of depressive symptoms in our study
population could be caused by psychological
distress from chronic stress due to unemploy-
ment and the burden of care for the disease. Our
result is similar to what was reported by a sys-
tematic review on depression assessment
among persons with HIV in Sub-Saharan Africa
Table 2 Severity of depression
Depression severity Frequency Percentage
Mild 70 23.3
Moderate 8 2.7




by Tsai et al. in 2014, who found a 29.5%
prevalence of probable depression [24]. These
similarities could exist because both studies had
similar study populations.
Our prevalence was higher than what was
obtained in other studies: Tung et al. (19%) and
Olisah in Nigeria (21.3%) and Joon in Korea
(21%) [25–27]. These differences could be due to
the differences in the instruments used to
Table 3 Demographic and social determinants of depression
Characteristic Total number (n5 300) Depression (n5 80)
Frequency (%)




Male 80 16 (20.0) 64 (80.0) 0.12
Female 220 64 (29.1) 156 (70.9)
Age
B40 159 51 (32.1) 108 (67.9) 0.02*
[40 141 29 (20.6) 112 (79.4)
Marital status
Married 140 29 (20.7) 111 (79.3) 0.03*
Unmarried 160 51 (31.9) 109 (68.1)
Educational level
No formal 174 45 (25.9) 129 (74.1) 0.71
Formal 126 35 (27.8) 91 (72.2)
Employment status
Employed 234 55 (23.5) 179 (76.5) 0.02*
Unemployed 66 25 (37.9) 41 (62.1)
Financial supporter
Self 196 55 (28.1) 141 (71.9) 0.45
Non-self 104 25 (24.0) 79 (75.0)
Living companion
No 56 23 (41.1) 33 (58.9) 0.01*
Yes 244 57 (23.4) 187 (76.6)
Alcohol consumption
No 280 75 (26.8) 205 (73.2) 0.86
Yes 20 5 (25.0) 15 (75.0)
Smoking
No 293 77 (26.3) 216 (73.7) 0.33
Yes 7 3 (42.9) 4 (57.1)
* Statistically signiﬁcant
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diagnose depression, sample sizes and differ-
ences in the study population. The study carried
out by Tung et al. had a smaller sample size and
the HADS was used to screen for depression
[25]. The use of PHQ-9 with a low cut-off (C5) in
terms of severity of depression will discover an
extra percentage of individuals with depressive
symptoms as opposed to the HADS screening
tool with a cut-off of HADS-D C8 [23]. Olisah
et al. studied adherence to highly active
antiretroviral therapy in depressed patients with
HIV/AIDS attending a Nigerian university
teaching hospital clinic. The Centre for Epi-
demiological Studies Depression Scale (CES-D)
was used to screen for depressive symptoms
[26]. Joon et al. used the Beck Depression
Inventory and had a smaller sample size [27].
However, the prevalence in our study was
lower than what was reported in other studies:
L’akoa in Cameroon (63%), Shittu in Nigeria
(56.7%), Nakimuli et al. in a systematic review
in SSA (31.2%) and Kitshoff in South Africa
(62%) [18, 28–30]. These differences could be
due to differences in the tools used, sample size
and the study population. The study by L’akoa
et al. was on newly diagnosed HIV patients [18].
Shittu et al. in their study included both HIV
patients on HAART and HAART-naı¨ve patients
[28]. Nakimuli et al. had a larger sample size
from a group of studies over a 5-year period as
Table 4 Clinical determinants of depression
Characteristic Total number (n5 300) Depression (n5 80)
Frequency (%)
No depression (n5 220)
Frequency (%)
p value
Duration from diagnosis of HIV (months)
\60 188 48 (25.5) 140 (74.5) 0.65
C60 112 32 (27.9) 80 (72.1)
Duration on treatment (months)
\60 189 49 (25.9) 140 (74.1) 0.71
C60 111 31 (27.9) 80 (72.1)
CD4 count cells/^l
B200 23 11 (52.2) 12 (47.8) 0.01*
[200 277 69 (24.9) 208 (75.1)
History of chronic illness
No 297 80 (26.9) 217 (73.1) 0.29
Yes 3 0 (0.0) 3 (100.0)
Family history of depression
No 297 80 (26.9) 217 (73.1) 0.29
Yes 3 0 (0.0) 3 (100.0)
HAART regimen
TLE 194 53 (27.8) 141 (72.2) 0.09
ZLN 69 18 (26.1) 51 (73.9)
TLLI 20 6 (30.0) 14 (70.0)
TLN 17 3 (17.7) 14 (82.3)
* Statistically signiﬁcant
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well as differences in study design (systematic
review vs. cross-sectional study) [31]. Kitshoff
et al. also used the CES-D to screen for depres-
sive symptoms [30].
This study showed that those who were
unmarried had a higher prevalence of depres-
sive symptoms. Unmarried people, especially
the divorced and widowed, are much more
likely to experience negative social determi-
nants than those who are married because they
carry the double stress of raising their children
by themselves and work. This was similar to
findings by Bhatia et al. [32]. In the study by
Shittu et al., depressive symptoms were similar
between married and unmarried patients [28].
In addition, unemployment was associated
with depressive symptoms. This may be because
economic instability leads to stress, frustration,
dysfunctional family life and feelings of worth-
lessness. Joon in Korea [27] and Kitshoff in
South Africa [30] also reported similar findings.
Also, those who did not have a living com-
panion had a higher prevalence of depressive
symptoms. This is in conformity with the liter-
ature, which says those who live alone are pre-
disposed to developing depression [33]. This
might be because loneliness predisposes them
to feeling worthless and having poor appetites
and concentration problems since they have no
one to talk to and confide in. Tung in Malaysia
did not find any significant association between
having a living companion and depressive
symptoms [25].
Our study showed that participants aged
B40 years had a higher prevalence of depressive
symptoms. This is in line with the literature
showing that most people experience depres-
sion between the ages of 20 and 40 [33]. This is
the age at which most people settle down in life.
The stigma associated with getting a job or
psychological disturbance of not having a life-
time partner due to their HIV status might
account for the increased depression rate. Other
studies found no significant association
between age and depressive symptoms [28].
Having a low CD4 count was associated with
depressive symptoms. This might be due to the
patients feeling discouraged and having loss of
interest despite taking medication and still
having a low CD 4 count level. L’akoa et al.
reported similar findings from a study in
Yaounde´ [18].
The prevalence of depressive symptoms was
higher in participants with a formal education,
indicating that the level of education plays an
important role in the prevalence of depression
in patients. This might because those with a
higher level of education have a better under-
standing of their illness and its symptoms. This
is similar to findings in Canada [34] where
respondents whose educational levels were less
than secondary education had the lowest rate of
depression and the highest prevalence rate of
depression was seen among those with tertiary
education. Our findings however contrast with
findings by Shittu in Nigeria [35] and Kitshoff in
South Africa [30].
Our study did not show a significant rela-
tionship between most clinical variables (dura-
tion from diagnosis of HIV infection, duration
on HAART, type of HAART regimen) and
depression. This is in line with findings in other
studies: Joon et al. [27] and Tung et al. [25]. This
Table 5 Multivariate analysis for factors associated with
depression
Variable Adjusted OR 95% CI p value
Marital status
Married Referent
Unmarried 1.23 0.68–2.25 0.49
Age
[40 Referent
B40 2.13 1.20–3.70 0.01*
Employment status
Employed Referent
Unemployed 2.38 1.26–4.50 0.01*
Living companion
Yes Referent
No 1.72 0.86–3.45 0.12
CD4 count cells/^l
[200 Referent
B200 3.70 1.45–9.09 0.01*
* Statistically signiﬁcant
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indicates that these variables have no effect on
the development of depression.
The non-adherence rate of all participants
was 47.3%; 75.0% of participants with depres-
sion were non-adherent to HAART compared to
37.3% of those without depression. The
expression of depressive symptoms such as loss
of interest, hopelessness, lack of energy and
poor concentration seen in depressive disorders
is likely to have contributed to non-adherence
to HAART in the participants with depression.
This is similar to the study by Olisah et al. on
adherence to highly active antiretroviral ther-
apy in depressed patients with HIV/AIDS
attending a Nigerian university teaching hos-
pital clinic where 63.6% of participants with
depressive disorder had poor adherence to
HAART [26]. These similarities could be due to
the similarities in the sample sizes used. This
prevalence is higher than that reported by
Afiong in Nigeria (40.1%) [36] and Samwel in
Kenya (18%) [4].
Limitations
• The study was hospital based and as such
some patients with depressive disorders were
unlikely to present to the hospital because of
their depressed state.
• The results of our study do not allow the
extension of such findings to a clinical
condition of major depression, which
requires a full clinical evaluation and pre-
sumably a specific treatment. Nonetheless,
our results emphasise that clinicians should
integrate the delivery of clinical care, tar-
geted interventions and counselling against
depressive symptoms through regular
appointments to avoid poorer outcomes.
These findings should stimulate clinicians
to evaluate depression when the patient is
not complying with the treatment.
• The use of self-report medication adherence
to assess medication adherence (MMAS) was
a limitation of this study. The patients might
over-report non-adherence to HAART.
• Our study was cross-sectional and designed
to determine the association of depression
with non-adherence to HAART. As such, it
could only determine whether there is an
association between depression and non-ad-
herence and not whether this association is a
cause-effect relationship. With the latter
aim, a prospective study is needed in which
depressed patients are followed up to deter-
mine whether they are subsequently non-ad-
herent to treatment.
• We could only assess the prevalence of
depressive symptoms and not the prevalence
of diagnosed depression because PHQ-9 is a
screening tool that is mainly suggestive
rather than diagnostic like other instruments
used for depression diagnosis.
CONCLUSION
The prevalence of depressive symptoms is high
(26.7%) in HIV patients and depressive symp-
toms are associated with non-adherence to
HAART. This implies that depressed HIV/AIDS
patients tend not to follow up their treatment
thereby increasing the possibility of complica-
tions and poor prognosis. Unemployment,
being unmarried, age B40 years, living alone
and CD4 counts B200 cells/ll were found to be
factors associated with occurrence of depressive
symptoms in HIV patients, with unemploy-
ment, age B40 years and CD4 counts
B200 cells/ll being independent factors. Many
more female than male HIV patients tend to
have depressive symptoms.
Thus, guidelines should be established for
routine assessment (screening) of mental
health, especially depressive symptoms of HIV
patients, to improve the compliance with
HAART and prognosis of the disease.
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